Last reviewed · How we verify

Idhifa — Competitive Intelligence Brief

Idhifa (ENASIDENIB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Isocitrate Dehydrogenase 2 Inhibitor. Area: Oncology.

marketed Isocitrate Dehydrogenase 2 Inhibitor Isocitrate dehydrogenase [NADP], mitochondrial Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Idhifa (ENASIDENIB) — Bristol-Myers Squibb. Idhifa works by blocking the IDH2 enzyme, which is mutated in some AML cells, to prevent the production of a toxic metabolite that promotes cancer growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Idhifa TARGET ENASIDENIB Bristol-Myers Squibb marketed Isocitrate Dehydrogenase 2 Inhibitor Isocitrate dehydrogenase [NADP], mitochondrial 2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Isocitrate Dehydrogenase 2 Inhibitor class)

  1. Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Idhifa — Competitive Intelligence Brief. https://druglandscape.com/ci/enasidenib. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: